Vaccine approvals included two immunizations for RSV and a new pentavalent meningococcal shot.
This year was a year of firsts in the immunization space1: In addition to the first vaccines to protect against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in older adults and the first RSV vaccine for use in pregnant people to protect newborns, 2023 saw the first vaccine for adults at increased risk of exposure to chikungunya virus made its debut. Additional approvals included a new meningococcal vaccine that simplifies a complex immunization schedule.
Exploring Challenges, Opportunities for Community Pharmacists in Tobacco Cessation
April 24th 2024By addressing integration barriers associated with implementing tobacco cessation programs in the community pharmacy, community pharmacists can “significantly impact public health by increasing access to effective cessation support,” wrote investigators.
Socioeconomic Disparities Persisted Alongside Improving Vaccination Rates In US Over 11-Year Period
April 16th 2024Findings indicating that socioeconomic disparities widened gaps in vaccination timeliness signal the need for increased efforts to promote timely vaccination among children from families with lower income and those without private insurance.